Medicina
Departamento
Hospital Duran i Reynals
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Duran i Reynals (83)
2024
-
Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)
Scientific Reports
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment
2023
-
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Haematologica, Vol. 108, Núm. 1, pp. 110-121
-
Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 1, pp. 57-64
-
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)
Bone Marrow Transplantation
-
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study
Journal of Geriatric Oncology, Vol. 14, Núm. 1
-
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
eClinicalMedicine, Vol. 65
-
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
PLoS ONE, Vol. 18, Núm. 5 May
-
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679
-
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580
2022
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392
-
Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC
Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10
-
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538
-
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols
British Journal of Haematology, Vol. 196, Núm. 3, pp. 670-675
-
Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors
Pathogens, Vol. 11, Núm. 10
-
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
2021
-
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Leukemia, Vol. 35, Núm. 10, pp. 2885-2894
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60